Tamoxifen (TAM)是一种选择性雌激素受体调节剂，用于治疗乳腺癌。由于视网膜、视网膜色素上皮和脉络膜中有雌激素受体，这些组织可能也会受到TAM的影响。我们描述了TAM对视网膜和脉络膜的报道效应。通过使用相关关键词搜索医学数据库，提取和汇总结果。视网膜/脉络膜毒性的发生率在0.9%至12%之间。TAM视网膜病变发展前的暴露时间范围很大（3周至13年）。虽然功能性测量可能适用于评估TAM视网膜病变，但它们对于筛选患者不起作用。没有普遍接受的筛查方法，但串行眼底镜检查和光学相干断层扫描成像似乎是检测早期TAM诱导的视网膜毒性的最合理方法。版权所有 © 2023 Elsevier Inc. 发布。

Tamoxifen (TAM) is a selective estrogen receptor modulator that is used in the treatment of breast cancer. As there are estrogen receptors in the retina, retinal pigment epithelium, and choroid, these tissues may also be affected by TAM. We describe the reported effects of TAM on the retina and choroid. Medical databases were searched using relevant keywords and the results were extracted and pooled. The incidence of retinal/choroidal toxicity ranged from 0.9% to 12%. There was a wide range for the time of exposure prior to the development of TAM retinopathy (3 weeks to 13 years). While functional measurements may be appropriate for assessment of TAM retinopathy, they have not been effective for screening patients. There is no generally accepted screening modality, but serial funduscopy and optical coherence tomography imaging seem to be the most reasonable approach for detecting early TAM-induced retinal toxicity.Copyright © 2023. Published by Elsevier Inc.